Precision BioSearch is delighted to present Kenji Hashimoto, the CMO of Crescendo Biologics with the ‘Best Established Biotech Company’ award at the OBN Awards 2021.

The OBN Award ceremony was held at the University of Oxford’s Ashmolean Museum and included 36 short-listed companies across 11 categories. Other finalists for the “Best Established Biotech Company” award included Healx and C4X Discovery.

The Crescendo team was nominated for their impressive progress in recent years, including the initiation of the CB307 clinical programme, trialling a novel half-life extended CD137 x PSMA Humabody®, as well as for numerous milestones achieved in their collaborations with Takeda and Zai Lab.

Theodora Harold, CEO of Crescendo, commented: “We are honoured that our achievements have been recognized by the judging panel at this year’s OBN Awards. It is a testament to our team’s hard work in developing our portfolio of T cell enhancing therapies for the benefit of cancer patients. We are very proud to receive the industry-wide recognition and to be part of such a vibrant community of exciting bioscience companies.

About Crescendo Biologics: a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

For more information, visit: www.crescendobiologics.com